Relative to placebo , both canagliflozin doses significantly reduced body weight ( -2.5 and -3.5 kg ) , fasting plasma glucose and systolic blood pressure ( BP ) at week 26 ( p < 0.05 for all ) , with reductions maintained at week 52 .